<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of HIV transmission during breastfeeding in resource-limited settings</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of HIV transmission during breastfeeding in resource-limited settings</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of HIV transmission during breastfeeding in resource-limited settings</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Grace John-Stewart, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynne M Mofenson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3841022005"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Postnatal human immunodeficiency virus (HIV) transmission occurs in utero, peripartum, and postnatally via breastfeeding; without interventions the risk of perinatal HIV-1 transmission is 20 to 45 percent [<a href="#rid1">1</a>].</p><p>Over the past two decades, clinical trials have demonstrated that the risk of vertical transmission can be significantly reduced with the administration of antiretroviral medications during pregnancy, delivery, and the postpartum period. Breastfeeding is important for the nutritional and overall health of the infant, and maternal antiretroviral therapy and infant antiretroviral prophylaxis have each been shown to substantially decrease HIV transmission during breastfeeding [<a href="#rid2">2,3</a>]. </p><p>This topic will discuss clinical data from resource-limited settings on the prevention of HIV transmission during the breastfeeding period. Advice on the use of antepartum and intrapartum antiretroviral prophylaxis for prevention of vertical HIV transmission in resource-limited settings are discussed in detail elsewhere in UpToDate and in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789240031593&amp;token=mr3MkQMxxRm373pPGLTYB%2B8L7rJeOJtqYOfpSLq18h7bLDDnWC3XicBcpsIGU3t1xXehdkIZVqQjh2ecP2j3bw%3D%3D&amp;TOPIC_ID=13970" target="_blank">World Health Organization consolidated guidelines on HIV prevention, testing, treatment, service delivery, and monitoring</a>. (See  <a class="medical medical_review" href="/z/d/html/3799.html" rel="external">"Prevention of vertical HIV transmission in resource-limited settings"</a>.)</p><p class="headingAnchor" id="H1758085"><span class="h1">EPIDEMIOLOGY OF HIV TRANSMISSION THROUGH BREASTFEEDING</span></p><p class="headingAnchor" id="H1808791"><span class="h2">Risk of HIV transmission through breast milk</span><span class="headingEndMark"> — </span>Breastfeeding contributes to a substantial proportion of new infant HIV infections [<a href="#rid4">4</a>]. Early evidence for HIV transmission via breast milk included detection of virus in breast milk, observational studies in which breastfed infants had higher transmission than non-breastfed infants, and cases in which women acquired HIV after pregnancy and then transmitted to their breastfeeding infant [<a href="#rid1">1</a>]. There have also been reports of infection in infants born to mothers without HIV but breastfed by surrogates with HIV [<a href="#rid5">5</a>]</p><p>HIV detection in infants during the first two weeks of life may represent transmission that has occurred in utero, during delivery, or within the early days of breastfeeding [<a href="#rid6">6</a>]. This complicates estimation of early breast milk HIV transmission risk during the first month of life. To try to distinguish potential transmission routes, most studies that have evaluated the risk of infant acquisition of HIV through breastfeeding have defined breastfeeding transmission as infant HIV infection detected at one month of life or later following a negative HIV virologic test.</p><p class="headingAnchor" id="H20403443"><span class="h2">Timing of HIV transmission through breast milk</span><span class="headingEndMark"> — </span>Data from clinical trials on prevention of vertical transmission of HIV suggest that the risk of transmission through breastfeeding is highest in early months of the infant's life [<a href="#rid7">7-9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Nairobi trial, which evaluated rates of HIV infant transmission among infants randomized to either breastfeeding or replacement feeding, 67 percent of the risk difference between the two trial arms occurred by two months while 75 percent occurred within six months [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of a Malawian cohort of 672 mother-infant pairs, HIV transmission risk declined as breastfeeding continued: 0.7 percent/month during months 1 through 5, 0.6 percent/month during months 6 through 11, and 0.3 percent/month during months 12 through 17 [<a href="#rid11">11</a>].</p><p></p><p>One meta-analysis (Breastfeeding and HIV International Transmission Study) suggested that the risk of <strong>late</strong> breast milk transmission (postnatal transmission occurring after one month of age) appeared relatively constant at 8.9 transmissions per 100 person-years of breastfeeding [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H1036418246"><span class="h2">Risk factors for HIV transmission through breast milk</span><span class="headingEndMark"> — </span>Clinical and laboratory data suggest that the most important factor affecting HIV transmission to the infant is the level of viremia in the mother [<a href="#rid13">13</a>]. Other risk factors that may affect HIV transmission to the infant include the mother's immunologic status, presence of maternal HIV drug resistance, presence of mastitis, and patterns of feeding. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maternal HIV viral load</strong> − Higher maternal plasma HIV ribonucleic acid (RNA) and breast milk HIV deoxyribonucleic acid (DNA) and RNA levels are associated with increased transmission risk [<a href="#rid13">13-15</a>]. In a case-control study of 92 infants with HIV and 187 infants without HIV, higher maternal viral RNA levels were associated with an increased risk in HIV transmission to the infant [<a href="#rid14">14</a>]. Nevertheless, some evidence suggests that plasma HIV suppression does not completely eliminate the risk of transmission through breast milk. (See <a class="local">'Transmission risk despite viral suppression'</a> below.)</p><p></p><p class="bulletIndent1">In a longitudinal assessment of 275 Kenyan mothers with HIV, a log increase of breast milk HIV RNA levels was associated with twofold higher risk of HIV transmission [<a href="#rid16">16</a>]. Several studies have suggested that levels of cellular HIV DNA in breast milk is more predictive of transmission than levels of cell-free HIV RNA in breast milk [<a href="#rid8">8,17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute versus chronic HIV infection </strong>− Observational data suggest acute maternal HIV infection during breastfeeding is associated with greater transmission risk to the infant than chronic maternal HIV infection. In meta-analyses of several observational studies, the risk of postnatal HIV transmission was significantly higher among women with acute versus chronic HIV infection (29 versus 14 percent in absence of antiretrovirals; 2.9-fold increased risk in studies including antiretrovirals); this observation may be related to the much higher level of HIV RNA seen in acute HIV infection [<a href="#rid7">7,18</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maternal immunologic factors</strong> − Several studies have noted increased transmission among immunosuppressed females with low CD4 cell counts [<a href="#rid1">1</a>]. This observation may be related to the higher viral burden in patients with advanced HIV disease, but maternal or infant immune status may confer some independent influence on transmission as well.</p><p></p><p class="bulletIndent1">HIV specific immunoglobulins (IgA and IgM), antibody-dependent cell cytotoxicity, and HIV-specific cytotoxic T cells are detected in breast milk and may influence HIV transmission through breastfeeding [<a href="#rid15">15,19-21</a>]. </p><p></p><p class="bulletIndent1">Detection of HIV-specific T cells in maternal breast milk was also associated with decreased HIV transmission [<a href="#rid22">22</a>]. Secretory leukocyte protease inhibitor (SLPI) is a protein found in saliva, breast milk, and genital secretions, which is capable of inhibiting HIV in vitro. Higher levels of SLPI in infant saliva have been associated with a lower risk of HIV acquisition [<a href="#rid23">23</a>], while SLPI levels in breast milk do not appear to modify transmission rates [<a href="#rid24">24-26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maternal presence of HIV drug resistance </strong>− Presence of HIV drug resistance in the mother may be associated with increased risk of postnatal HIV transmission through breast milk, independent of maternal viral load. In a case-control study of 148 breast fed infants (37 with postnatally acquired HIV and 111 without HIV), presence of HIV drug resistance in the mother was associated with postnatal transmission, independent of maternal HIV viral load (odds ratio 4.45) [<a href="#rid27">27</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast infections</strong> − Mastitis and breast abscess have been associated with an increased risk of HIV transmission, which may be due to the increased recruitment of HIV-infected inflammatory cells in an area of infection [<a href="#rid14">14,28-32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patterns of feeding</strong> − Mixed feeding (breastfeeding along with ingestion of solids/liquids) during the first three to six months of life is associated with an increased risk of infant HIV transmission compared with breastfeeding alone in infants of mothers not receiving antiretroviral therapy. This is further discussed elsewhere. (See <a class="local">'Efficacy of alternative feeding strategies'</a> below.) </p><p></p><p class="headingAnchor" id="H1036418697"><span class="h2">Mechanism of breast milk transmission</span><span class="headingEndMark"> — </span>The mechanism of transmission of HIV through breast milk has not been fully elucidated. HIV RNA can be detected in colostrum and breast milk [<a href="#rid7">7,33</a>], but some studies suggest that HIV-infected cells within breast milk may play a more important role in infant transmission than cell-free virus [<a href="#rid8">8,9</a>]. Additionally, the portal of entry of HIV in the breastfed infant has not been defined but may include the intestine or tonsillar tissues. </p><p>Breaches in intestinal epithelial integrity or compromise in intestinal cellular tight junctions (eg, between epithelial or dendritic cells) may allow entry of infectious virions [<a href="#rid26">26,34-36</a>]. Infants who become infected via breastfeeding have higher levels of lipopolysaccharide, suggesting that compromised gut integrity may facilitate transmission [<a href="#rid37">37</a>]. The possibility of HIV entry into tonsillar lymphocytes has been suggested from studies of a related virus (ie, simian immunodeficiency virus) in infant macaques [<a href="#rid38">38-40</a>]. </p><p class="headingAnchor" id="H1036418861"><span class="h1">RECOMMENDATIONS TO PREVENT TRANSMISSION DURING BREASTFEEDING</span><span class="headingEndMark"> — </span>The use of antiretroviral agents is a critical component of prevention of vertical transmission during antepartum, peripartum, and early postpartum periods (see  <a class="medical medical_review" href="/z/d/html/3799.html" rel="external">"Prevention of vertical HIV transmission in resource-limited settings"</a>). During breastfeeding, maternal combination antiretroviral therapy (ART) and infant antiretroviral prophylaxis strategies are each comparably effective at reducing the risk of transmission [<a href="#rid3">3</a>]. Efforts to diagnose, treat, and retain individuals on ART during pregnancy and breastfeeding and efforts to prevent new infant HIV infections after birth will all be necessary to attain elimination of infant HIV. The World Health Organization (WHO) recommends maternal ART to reduce transmission during breastfeeding, as this benefits maternal health and decreases risk of infant HIV and simplifies antiretroviral management of pregnant and breastfeeding females through the entire period of transmission risk [<a href="#rid41">41,42</a>]. WHO guidelines recommend lifelong ART for all individuals with HIV, including pregnant and breastfeeding females [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">"When to initiate antiretroviral therapy in persons with HIV", section on 'Introduction'</a>.) </p><p>Infant antiretroviral use remains important as short-term postexposure prophylaxis after delivery and in settings in which maternal antiretroviral use is delayed or interrupted during breastfeeding.</p><p>Details on the duration of breastfeeding and the timing and selection of antiretroviral regimens are discussed below. </p><p class="headingAnchor" id="H1036418907"><span class="h2">Options for infant feeding</span><span class="headingEndMark"> — </span>Recommendations on infant feeding must balance the risk of HIV transmission through breast milk on one hand and the risk of malnutrition and serious infections through unsafe feeding practices on the other (see <a class="local">'Replacement feeding'</a> below). The WHO recommends that for mothers known to have HIV, public health authorities should focus either on promoting breastfeeding and providing antiretroviral interventions to prevent transmission or on avoiding all breastfeeding and providing alternate sources of safe nutrition [<a href="#rid41">41,43</a>]. Promoting breastfeeding with antiretroviral interventions is the better strategy in most resource-limited settings. In an analysis of pooled data from studies in Asia and Africa, lack of breastfeeding was associated with mortality in HIV-exposed but uninfected infants [<a href="#rid44">44</a>]. Maternal ART during breastfeeding use was associated with lower child mortality rates.</p><p class="headingAnchor" id="H2228179508"><span class="h3">Exclusive breastfeeding protocol</span><span class="headingEndMark"> — </span>For females with HIV in those countries that have chosen to support breastfeeding with antiretroviral interventions, the WHO recommends exclusive breastfeeding for six months, in combination with maternal ART and a short-term period of infant prophylaxis, to minimize HIV transmission from the mother while optimizing the health benefits of breastfeeding for the infant [<a href="#rid41">41,45</a>]. Subsequently, breastfeeding, along with maternal ART (with provision of ART adherence support) and appropriate complementary feeding, should continue without restrictions for up to 24 months or longer, similar to the general population [<a href="#rid46">46</a>]. </p><p>Earlier studies suggested that exclusive breastfeeding was difficult to implement given cultural or logistic constraints with &lt;10 percent of females implementing exclusive breastfeeding despite counseling [<a href="#rid47">47,48</a>]. With expanded counseling and home visits, higher levels of exclusive breastfeeding are possible, with some studies reporting &gt;80 percent of females with HIV exclusively breastfeeding at three months postpartum [<a href="#rid49">49-51</a>]. Breastfeeding support at delivery has been associated with increased prevalence of exclusive breastfeeding at six weeks [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H1036418913"><span class="h2">Maternal antiretroviral use</span></p><p class="headingAnchor" id="H1036418940"><span class="h3">When to initiate an antiretroviral regimen</span><span class="headingEndMark"> — </span>The WHO guidelines recommend initiation of ART for all pregnant or breastfeeding females with HIV, regardless of their CD4 cell count, to reduce the risk of transmission to their infants and for their own clinical benefit [<a href="#rid41">41</a>]. Breastfeeding females already taking ART should continue it. For other females, an ART regimen should be initiated as soon as possible (eg, as soon as a female with HIV is found to be breastfeeding or as soon as HIV is diagnosed in a breastfeeding female) [<a href="#rid41">41</a>]. Maternal ART has multiple benefits, including prevention of HIV transmission to the infant, improved long-term infant HIV-free survival, maternal health, and prevention of HIV transmission to sexual partners [<a href="#rid41">41,42,44,53</a>].</p><p>Data from trials of maternal antiretroviral use to prevent transmission during breastfeeding suggest that earlier initiation of combination antiretroviral drug regimens during or before pregnancy (rather than at delivery) is associated with a lower risk of infant transmission [<a href="#rid54">54</a>]. This is because of the time that it takes for antiretroviral agents to lead to complete viral suppression. (See <a class="local">'Efficacy of antiretroviral drugs to prevent transmission during breastfeeding'</a> below.)</p><p class="headingAnchor" id="H1036418946"><span class="h3">Regimen selection</span><span class="headingEndMark"> — </span>The WHO guidelines recommend initiation of <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a>, <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> (or <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">emtricitabine</a>), and <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> in pregnant or breastfeeding females with HIV [<a href="#rid41">41</a>]. Although rare neural tube defects have been observed among females receiving dolutegravir at the time of conception in observational cohorts [<a href="#rid55">55,56</a>], further accumulation of data demonstrates no difference in risk of neural tube defects between dolutegravir-based and non-dolutegravir based regimens [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/3778.html" rel="external">"Safety and dosing of antiretroviral medications in pregnancy", section on 'Dolutegravir'</a>.)</p><p>The tenofovir, <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> (or <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">emtricitabine</a>), and <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> regimen aligns with recommendations for all adults in resource-limited settings. While neither the tenofovir, lamivudine (or emtricitabine), and dolutegravir nor tenofovir, lamivudine (or emtricitabine), and <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a> has been explicitly studied in trials of preventing HIV transmission during breastfeeding, both result in viral suppression in the majority of individuals [<a href="#rid58">58,59</a>], which is the most important clinical factor affecting the risk of postnatal transmission (see <a class="local">'Risk factors for HIV transmission through breast milk'</a> above). A multicenter, randomized trial compared dolutegravir versus efavirenz in combination with lamivudine (or emtricitabine) and either <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> or <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">tenofovir alafenamide</a> and found that dolutegravir-containing regimens had superior virologic efficacy at delivery compared with efavirenz [<a href="#rid60">60</a>]. Although the tenofovir alafenamide (TAF) regimen (compared with tenofovir disoproxil fumarate) had a better safety profile with fewer composite adverse pregnancy outcomes, TAF is not widely available in resource-limited settings. Other randomized trials found more rapid viral decline with dolutegravir-based then efavirenz-based regimen and persistent maternal viral suppression during breastfeeding [<a href="#rid61">61,62</a>].</p><p>Any maternal ART regimen that results in virologic suppression should result in significantly decreased perinatal and postnatal transmission. For example, a protease inhibitor-based regimen used in one large trial resulted in an 18-month postnatal transmission rate of only 0.6 percent [<a href="#rid3">3</a>]; in a separate study comparing an efavirenz-based regimen with a lopinavir-ritonavir-based regimen, infant 12-month transmission rates were similarly low [<a href="#rid3">3,63</a>]. </p><p>Discussion of alternative WHO-recommended first-line or second-line regimens is also found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13980.html" rel="external">"Use and impact of antiretroviral therapy for HIV infection in resource-limited settings", section on 'Regimen selection'</a>.)</p><p class="headingAnchor" id="H337866513"><span class="h3">Acute HIV infection postpartum</span><span class="headingEndMark"> — </span>In regions with high HIV seroprevalence, females may be at risk for acquiring HIV during the breastfeeding period. Females who acquire HIV during breastfeeding have a high risk of transmitting HIV to their breastfeeding infant [<a href="#rid18">18</a>]. Thus, acute or early HIV in the postpartum period warrants immediate ART with the same regimens discussed above, in addition to at least 12 weeks of enhanced antiretroviral prophylaxis for breastfeeding infants. (See <a class="local">'Regimen selection'</a> above and <a class="local">'Infant antiretroviral use'</a> below.)</p><p class="headingAnchor" id="H337866439"><span class="h3">Maintaining retention and adherence to antiretrovirals during breastfeeding</span><span class="headingEndMark"> — </span>Adherence counseling approaches may need to be adapted for this period. Specific counseling may be needed to help females continue antiretrovirals during breastfeeding, particularly after nine months when visits to maternal child health centers may decrease. A variety of other approaches have been evaluated to improve retention and adherence, including lay counselors, cash transfers, engagement of partners, and health interventions; some have had positive results [<a href="#rid64">64-68</a>].</p><p class="headingAnchor" id="H1036418958"><span class="h2">Infant antiretroviral use</span></p><p class="headingAnchor" id="H1036418964"><span class="h3">Breastfeeding infants</span><span class="headingEndMark"> — </span>For breastfeeding infants, the purpose of antiretroviral prophylaxis is to prevent transmission from exposure to HIV during delivery and the early breastfeeding period, as well as during any periods of breastfeeding when the mother may not have virologic suppression. All breastfeeding infants born to mothers with HIV should receive antiretroviral prophylaxis [<a href="#rid41">41</a>]. The recommended regimen depends on the infant’s risk of infection, as determined by the timing of maternal infection and ART use  (<a class="graphic graphic_algorithm graphicRef108808" href="/z/d/graphic/108808.html" rel="external">algorithm 1</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>For infants born to mothers with established HIV who, by the time of delivery, had achieved viral suppression on ART or had been regularly taking ART for more than four weeks, we recommend daily <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a> for six weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For infants born to mothers with HIV who had a viral load &gt;1000 copies/mL within the four weeks prior to expected delivery, who received no ART or less than four weeks of ART by the time of delivery, or who acquired HIV during pregnancy or breastfeeding, we recommend daily <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a> PLUS twice-daily <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a> for six weeks, followed by an additional six weeks of the same combination regimen or nevirapine alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For infants identified after birth as having been exposed to HIV, a virologic diagnostic test should be performed. In addition to initiation of maternal ART, the infant should start daily <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a> plus twice-daily <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a> immediately and continue for at least six weeks. This should be followed by an additional six weeks of either nevirapine plus zidovudine or nevirapine alone. If the virologic test identifies that the infant has HIV, infant prophylaxis should be stopped and combination ART initiated. The WHO recommends that a raltegravir-based antiretroviral regimen should be first-line therapy for all children with HIV under the age of one month [<a href="#rid41">41</a>]. <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">Dolutegravir</a> is approved for children older than one month who weigh more than 3 kg. </p><p></p><p>In the unusual circumstance of a mother who cannot tolerate or declines ART, the infant should continue <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a> prophylaxis throughout the duration of breastfeeding, until one week following breastfeeding cessation (if nevirapine is not tolerated, daily <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> can be used).</p><p><a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">Nevirapine</a> and <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a> dosing are based on the weight of the infant  (<a class="graphic graphic_table graphicRef108738" href="/z/d/graphic/108738.html" rel="external">table 1</a>). </p><p>A disadvantage of infant prophylaxis is the risk of developing HIV drug resistance if the infant does acquire infection during breastfeeding. Additionally, drug resistance has also been observed in infants who become infected despite maternal combination drug use during breastfeeding [<a href="#rid69">69-71</a>]. However, since the effectiveness of nevirapine-based prophylaxis in preventing transmission among breastfeeding infants is high, the overall risk of drug resistance among infants receiving prophylaxis is low. </p><p class="headingAnchor" id="H1036418970"><span class="h3">Infants on replacement feeding</span><span class="headingEndMark"> — </span>For infants who receive replacement feeding instead of their mothers' breast milk, the purpose of infant antiretroviral prophylaxis is to prevent transmission from exposure to HIV during delivery. All replacement feeding infants born to mothers with HIV should receive antiretroviral prophylaxis [<a href="#rid41">41</a>]. The recommended regimen depends on the infant’s risk of infection, as determined by the timing of maternal infection and ART use  (<a class="graphic graphic_algorithm graphicRef108808" href="/z/d/graphic/108808.html" rel="external">algorithm 1</a>). This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3799.html" rel="external">"Prevention of vertical HIV transmission in resource-limited settings", section on 'Infant postnatal prophylaxis'</a>.) </p><p>Infants who are identified more than 24 hours after birth as having been exposed to HIV should have a virologic diagnostic test performed. Uninfected infants who are using replacement feeding do not need antiretroviral prophylaxis because there is no ongoing risk of transmission through breast milk, and the period for effective prophylaxis of intrapartum transmission may be passed (eg, infant prophylaxis initiated 24 to 48 hours or more after birth is unlikely to affect intrapartum transmission). Combination ART should be initiated if the child is diagnosed with HIV. The WHO recommends that a raltegravir-based antiretroviral regimen should be first-line therapy for all children with HIV under the age of one month [<a href="#rid41">41</a>]. <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">Dolutegravir</a> is approved for children older than one month who weigh more than 3 kg [<a href="#rid41">41</a>]. </p><p class="headingAnchor" id="H1809829"><span class="h1">EFFICACY OF ANTIRETROVIRAL DRUGS TO PREVENT TRANSMISSION DURING BREASTFEEDING</span><span class="headingEndMark"> — </span>Clinical trials have demonstrated that the use of antiretroviral medications during pregnancy, labor, and delivery effectively reduces intrauterine and intrapartum HIV transmission from 24 percent to approximately 1 percent [<a href="#rid53">53,72,73</a>] (see  <a class="medical medical_review" href="/z/d/html/3799.html" rel="external">"Prevention of vertical HIV transmission in resource-limited settings"</a>). However, without ongoing prophylaxis after delivery, one meta-analysis demonstrated that an additional 9 percent of infants who are born to mothers with HIV will become infected after one month of age through breastfeeding [<a href="#rid74">74</a>]. Fortunately, several randomized trials and observational studies in resource-limited settings have shown that use of antiretroviral medications by the mother or infant during breastfeeding can substantially reduce rates of late postnatal HIV transmission to the infant to less than 3 percent [<a href="#rid13">13,75-77</a>], and in a more recent study, down to 0.6 percent at 18-months of follow-up [<a href="#rid3">3</a>].</p><p>The discussion below highlights some of the main concepts that have emerged within the last several years regarding the most effective use of antiretroviral medications for the prevention of HIV during breastfeeding. Drugs that have been studied include <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a>, which is a nonnucleoside reverse transcriptase inhibitor (NNRTI); <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a>, <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a>, and <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a>, which are nucleoside reverse transcriptase inhibitors (NRTI); lopinavir/<a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a>, which are protease inhibitors (PI); <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a>, which is an integrase inhibitor. (See  <a class="medical medical_review" href="/z/d/html/3778.html" rel="external">"Safety and dosing of antiretroviral medications in pregnancy"</a>.)</p><p class="headingAnchor" id="H1036419764"><span class="h2">Efficacy of maternal antiretroviral drug use</span><span class="headingEndMark"> — </span>Several studies have demonstrated that pregnant and breastfeeding females who achieve virologic suppression on antiretroviral agents have low rates of HIV transmission to their infants, with reported rates ranging from &lt;1 to 5 percent [<a href="#rid3">3,13,75,76,78-80</a>]. This supports the observation that there is a significant association between the level of the mother's viral load and HIV infant transmission (see <a class="local">'Risk factors for HIV transmission through breast milk'</a> above). Since several weeks may lapse before viral suppression can be achieved following initiation of antiretroviral agents, drugs should be initiated before or during pregnancy, rather than at delivery, to maximally reduce infant HIV transmission as illustrated in the studies discussed here [<a href="#rid81">81</a>].</p><p>In the Mma Bana trial in Botswana, 560 women with CD4 cell counts ≥200 cells/microL were randomly assigned to receive either triple NRTIs (<a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a>, <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a>, and <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a>) or a PI-containing regimen (<a class="drug drug_general" data-topicid="9982" href="/z/d/drug information/9982.html" rel="external">lopinavir-ritonavir</a> with zidovudine and lamivudine) [<a href="#rid13">13,82</a>]. The regimen was initiated between 26 and 34 weeks of gestation and continued through weaning or six months postpartum (whichever occurred first). All infants also received short-term postnatal antiretroviral prophylaxis; 97 percent breastfed for a median of 5.8 months. Women with advanced immunosuppression (CD4 cell counts &lt;200 cells/microL) were placed in the observational group and initiated on chronic antiretroviral therapy (ART) with <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a>, zidovudine, and lamivudine for their own health. High rates of maternal viral suppression to &lt;400 copies/mL were seen in both groups (96 percent in the NRTI group versus 93 percent in the PI group). The overall rate of mother-to-child transmission was 1.1 percent. This rate is similar to that seen among treated females in resource-rich settings who did not breastfeed [<a href="#rid13">13,82,83</a>]. Because of the low number of maternal-infant transmissions (eight cases total), the effect of specific immunologic or virologic thresholds on the risk of transmission could not be analyzed. Rates of adverse events were similar in the NRTI and PI groups (6 percent each). However, there was a significantly higher rate of preterm delivery in the PI group than the NRTI group (23 versus 15 percent, respectively). (See  <a class="medical medical_review" href="/z/d/html/3778.html" rel="external">"Safety and dosing of antiretroviral medications in pregnancy", section on 'Preterm birth'</a>.)</p><p>Similarly, the multisite PROMISE trial, conducted in sub-Saharan Africa and India, demonstrated a transmission rate of 0.3 percent at six months and 0.6 percent at 12 months postpartum among breastfeeding women who continued PI-based ART for the duration of breastfeeding [<a href="#rid3">3</a>].</p><p>Observational studies have found somewhat higher overall transmission rates of approximately 3 to 5 percent with use of combination antiretroviral regimens in breastfeeding women [<a href="#rid75">75,79</a>]. For example, an observational study in Mozambique of mothers with HIV who were provided antenatal and postnatal antiretroviral medications for six months (mainly <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a> or <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">stavudine</a> in combination with <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> and <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a>) demonstrated an overall HIV infant transmission rate of 2.8 percent at 12 months [<a href="#rid76">76</a>]. </p><p>In the Breastfeeding, Antiretrovirals, and Nutrition (BAN) trial, the postnatal risk of HIV transmission was 2.9 percent in infants of mothers who were randomly assigned to receive a combination antiretroviral regimen started at two weeks postpartum delivery until weaning at 26 to 28 weeks [<a href="#rid2">2</a>]. In this study, there was a delay of 12 weeks in the effect of maternal antiretroviral use, which reflects the time needed to achieve virologic suppression. This suggests that earlier initiation of antiretrovirals during pregnancy would further decrease the risk of infant HIV transmission. The BAN trial is discussed in greater detail elsewhere. (See <a class="local">'Efficacy of maternal versus infant antiretroviral prophylaxis'</a> below.)</p><p class="headingAnchor" id="H1809848"><span class="h2">Efficacy of infant antiretroviral prophylaxis</span><span class="headingEndMark"> — </span>Several trials have demonstrated the success of infant antiretroviral prophylaxis in decreasing the risk of HIV acquisition during breastfeeding [<a href="#rid2">2,84-86</a>]. <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">Nevirapine</a> is effective as a single prophylactic agent and does not appear to have significant safety concerns when used in infants; <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a> may not add any additional benefit for prevention of transmission and may increase the risk of anemia [<a href="#rid2">2,85</a>].</p><p>In a pooled analysis of data from 5,396 mother-infant pairs included in five randomized trials that evaluated the prevention of HIV transmission during breastfeeding, a longer duration of infant <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a> prophylaxis was associated with a greater reduction in the risk of HIV infection [<a href="#rid87">87</a>]. This finding was confirmed in a subsequent clinical trial of 1,527 breastfeeding infants born to mothers with HIV in four African countries that evaluated the incremental benefit of extended nevirapine prophylaxis [<a href="#rid86">86,88</a>]. All infants received nevirapine from birth to six weeks; subsequently the infants were randomly assigned to either extended nevirapine prophylaxis or placebo until six months of follow-up or until breastfeeding cessation, whichever came first. Compared with six weeks of infant nevirapine followed by placebo, extended nevirapine prophylaxis reduced postnatal transmission of HIV by 54 percent at six months (2.4 percent placebo versus 1.1 percent extended nevirapine) but not subsequently [<a href="#rid88">88</a>]. More prolonged infant prophylaxis is also feasible and effective, as illustrated by a randomized trial of over 1,000 HIV-exposed infants, in which the postnatal transmission rate at 50 weeks was 1.4 to 1.5 percent with infant prophylaxis with daily <a class="drug drug_general" data-topicid="9982" href="/z/d/drug information/9982.html" rel="external">lopinavir-ritonavir</a> or <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> during breastfeeding for a median of 41 weeks [<a href="#rid89">89</a>]. </p><p>The PROMISE trial, which evaluated even longer infant prophylaxis, reported very low transmission rates (0.57 percent) with daily infant <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a> prophylaxis for 18 months and no maternal ART during breastfeeding [<a href="#rid3">3</a>]. A similar low rate of transmission was observed with maternal ART and only six weeks of infant nevirapine during breastfeeding, as discussed in detail below. (See <a class="local">'Efficacy of maternal versus infant antiretroviral prophylaxis'</a> below.)</p><p class="headingAnchor" id="H1809914"><span class="h2">Efficacy of maternal versus infant antiretroviral prophylaxis</span><span class="headingEndMark"> — </span>Maternal combination ART or infant <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a> prophylaxis decreases the risk of HIV transmission during breastfeeding with similar efficacy. However, given the WHO recommendation of lifelong ART for all individuals with HIV, including pregnant and breastfeeding females, maternal ART is the preferred strategy for prevention of breast milk transmission. (See <a class="local">'Recommendations to prevent transmission during breastfeeding'</a> above.)</p><p>The PROMISE trial was a large, randomized controlled trial conducted in 14 sites in sub-Saharan Africa and India that demonstrated no difference in postnatal HIV transmission rates with maternal ART versus infant prophylaxis during 24 months of breastfeeding [<a href="#rid3">3</a>]. Among 2,431 total mother-infant pairs, postnatal HIV infection occurred in 7 of 1,219 infants in the maternal treatment arm (0.57 percent) and 7 of 1,211 infants in the <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a> prophylaxis arm (0.58 percent, hazard ratio 1.0, 95% repeated CI 0.3-3.1). Infant HIV-free survival was high in both arms (97.1 and 97.7 percent with maternal treatment and infant prophylaxis, respectively). The overall low postnatal transmission rates in this trial reflect that all women enrolled in the PROMISE study had received maternal antepartum antiretroviral drugs.</p><p>The similar HIV transmission rates with the two prevention strategies in the PROMISE trial are consistent with findings from the earlier BAN trial, which was the first trial to assess the relative effectiveness of maternal or infant antiretroviral interventions compared with controls for prevention of HIV transmission to infants [<a href="#rid2">2</a>]. In this trial, mother-infant pairs were randomly assigned at delivery to a maternal regimen group, an infant regimen group, or neither intervention (the control group). Mothers who were enrolled had a CD4 cell count ≥ 250 cells/microL. The infant regimen included daily <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a> alone for 28 weeks; the maternal combination drug regimen varied during the trial due to emerging safety data related to individual agents (eg, hypersensitivity reactions and nevirapine use in women with CD4 counts &gt;250 cells). Most of the women in the trial received <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a>, <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a>, and ritonavir-boosted lopinavir. Perinatal antiretroviral prophylaxis (single-dose nevirapine plus one week of zidovudine and lamivudine) for the prevention of vertical transmission was given at delivery to all mothers and infants according to the contemporaneous standard of care. Women were advised to exclusively breastfeed during the study until 24 to 28 weeks when they were then instructed to rapidly wean. Maternal antiretrovirals were discontinued one week after weaning. The primary efficacy endpoint was the rate of detection of HIV infection at 28 weeks postpartum among infants who were uninfected at two weeks of life between the two intervention arms compared to the control arm. The trial demonstrated that either a maternal regimen of combination antiretroviral medications or an infant regimen of daily nevirapine were both effective in reducing the risk of HIV transmission (cumulative postnatal risk 2.9 percent and 1.7 percent, respectively) compared with controls (5.7 percent). The effectiveness of infant prophylaxis was evident by six weeks, while the relative effectiveness of maternal ART was only first apparent at 12 weeks. After 18 weeks of age, the risk of infection was similar between the two arms. This delayed effect in the maternal ART arm may be related to the time needed to attain maternal viral suppression, since ART was first initiated at delivery. The study did not assess the association between HIV RNA detection and risk of infant transmission. </p><p>An analysis of 48 week outcomes of the BAN trial demonstrated that, although the cumulative risk of HIV transmission still remained less in the maternal and infant prophylaxis arms (4 percent in both) than in the control group (7 percent), the transmission events that occurred after 28 weeks (when all prophylaxis had been discontinued) were evenly distributed across all groups [<a href="#rid90">90</a>]. Half of the late infections occurred at least 42 days after the reported cessation of breastfeeding. Furthermore, overall infant morbidity increased from 0.7 adverse events per 1000 person-weeks during the intervention period to 1.1 events per 1000 person-weeks after week 28, which correlated with the time when women weaned their infants. Although the study was not designed to evaluate the effect of early weaning, its results suggest that in resource-limited settings, instructing women to cease breastfeeding early at 24 to 28 weeks may not be an effective strategy against further HIV transmission and, as seen in other studies, may be associated with increased infant morbidity and mortality. (See <a class="local">'Shortened breastfeeding'</a> below.)</p><p class="headingAnchor" id="H2263567828"><span class="h2">Transmission risk despite viral suppression</span><span class="headingEndMark"> — </span>Although there is strong evidence that HIV is not sexually transmitted when the viral load is undetectable, results from breastfeeding cohorts suggest that the concept that undetectable equals untransmissible ("U=U") may not apply to breast milk transmission [<a href="#rid91">91-93</a>]. This may be due to higher persistent exposure, local activation, or other factors. </p><p>In a systematic review among women on ART during breastfeeding, the pooled transmission risk at 12 months was 2.93 percent [<a href="#rid92">92</a>]. It is likely that not all breastfeeding women in this review were actually virally suppressed, despite receiving ART. However, in the PROMISE trial, two of seven HIV transmissions during breastfeeding occurred among women on ART with viral loads &lt;40 copies/mL near the time of transmission [<a href="#rid93">93</a>]. Further evidence in this area will be useful for females in other settings to make informed decisions regarding breast or replacement feeding.</p><p class="headingAnchor" id="H1159929"><span class="h1">PENETRATION OF ANTIRETROVIRAL MEDICATIONS INTO BREAST MILK</span><span class="headingEndMark"> — </span>The ability of an antiretroviral drug to pass from a mother receiving antiretroviral therapy into the breast milk could potentially affect efficacy of the drug for preventing postnatal infection. While drugs with more penetration into breast milk may have greater efficacy, such penetration could also be associated with a risk of toxicity in the breastfeeding infant.</p><p>A systematic review of pharmacokinetic studies that measured drugs in breast milk of women with HIV taking antiretrovirals identified 24 relevant studies and suggested that infants would be exposed to quantitatively important levels of some nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) through ingestion of breast milk [<a href="#rid94">94</a>]. While there was substantial variability in the clinical and laboratory methods used, NRTIs such as <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> and <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a> showed accumulation in breast milk relative to maternal plasma, with breast milk to maternal plasma ratios ranging from 0.89 to 1.21. For NNRTIs such as <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a> and <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a>, ratio estimates ranged from 0.71 to 0.94, and for protease inhibitors such as <a class="drug drug_general" data-topicid="9982" href="/z/d/drug information/9982.html" rel="external">lopinavir-ritonavir</a>, they ranged from 0.17 to 0.21. The review estimated that, relative to recommended pediatric doses, a breastfed infant may ingest 8.4, 12.5, and 1.1 percent of lamivudine, nevirapine, and efavirenz, respectively, via breast milk. </p><p>In an intensive pharmacokinetic evaluation of samples from maternal and infant blood and breast milk, <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">emtricitabine</a> and <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> accumulated in breast milk and were detected in breastfeeding infants, whereas tenofovir had limited penetration into breast milk and was undetectable in breastfeeding infants [<a href="#rid95">95</a>]. Similar findings related to tenofovir were observed in a study of infants of women without HIV receiving tenofovir for pre-exposure prophylaxis, with tenofovir undetectable in 94 percent of infant plasma specimens [<a href="#rid96">96</a>]. <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">Dolutegravir</a> levels in breast milk have been observed to be 3 percent of plasma concentration, with significant infant levels (3 to 8 percent of maternal exposure); maternal dolutegravir dosing that is stopped at delivery is estimated to result in subsequent exposure through breastfeeding equivalent to 4.5 days of infant prophylaxis [<a href="#rid61">61,97,98</a>].</p><p class="headingAnchor" id="H64402186"><span class="h1">DRUG TOXICITY CONCERNS</span></p><p class="headingAnchor" id="H20403834"><span class="h2">Maternal toxicity</span><span class="headingEndMark"> — </span>The antiretroviral regimens used in clinical trials of preventing vertical transmission of HIV were relatively well tolerated. <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">Nevirapine</a> has been associated with the most adverse effects. In the Breastfeeding, Antiretrovirals, and Nutrition (BAN) trial, the rate of neutropenia with nevirapine was 6.2 percent, and 6 of 39 women who initially received a nevirapine-containing regimen developed a hypersensitivity reaction, including two with Stevens-Johnson syndrome [<a href="#rid2">2</a>]. Side effects associated with specific antiretroviral agents among pregnant and breastfeeding females are largely the same as those experienced in the general population with HIV. (See  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3778.html" rel="external">"Safety and dosing of antiretroviral medications in pregnancy"</a>.) </p><p class="headingAnchor" id="H2568674"><span class="h2">Fetal and infant toxicity</span><span class="headingEndMark"> — </span>Adverse birth outcomes, such as low birth weight, stillbirth, prematurity, and small for gestational age have been an issue of concern with the use of antiretroviral medications during pregnancy [<a href="#rid83">83</a>]. (See  <a class="medical medical_review" href="/z/d/html/3799.html" rel="external">"Prevention of vertical HIV transmission in resource-limited settings", section on 'Adverse effects/safety'</a>.)</p><p>Some, but not all, studies have reported elevated rates of hematologic toxicity among breastfeeding infants of mothers who were receiving zidovudine-based combination antiretroviral regimens during pregnancy and/or breastfeeding [<a href="#rid99">99-101</a>]. However, studies that have evaluated the impact of breast milk exposure to tenofovir-lamivudine-efavirenz (the recommended antiretroviral regimen) on infant laboratory values, growth, and markers of bone growth or resorption have not shown evidence of toxicity in the breastfeeding infant [<a href="#rid102">102-104</a>]. </p><p>Infant administration of <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a>, <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a>, and <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> have all been studied for extended infant HIV prophylaxis. Postnatal infant zidovudine is associated with hematologic toxicity and does not appear to provide any additive benefit in preventing transmission over nevirapine alone [<a href="#rid85">85</a>]. Infant prophylaxis with lamivudine was well tolerated in one open-label prospective study and non-inferior to <a class="drug drug_general" data-topicid="9982" href="/z/d/drug information/9982.html" rel="external">lopinavir-ritonavir</a> prophylaxis [<a href="#rid89">89,105</a>]. In the BAN trial, a small percentage of infants receiving daily nevirapine (&lt;2 percent) developed a hypersensitivity reaction, which resolved in all cases with discontinuation of nevirapine and substitution of lamivudine as the infant prophylaxis regimen. In the PROMISE study, in which breastfeeding infants received 18 months of daily nevirapine, toxicity rates were low and similar to breastfeeding infants receiving only six weeks of daily nevirapine (with exposure to maternal lopinavir-ritonavir-based antiretroviral therapy) [<a href="#rid3">3</a>].(See  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV", section on 'Non-nucleoside reverse transcriptase inhibitors (NNRTIs)'</a>.)</p><p class="headingAnchor" id="H13613012"><span class="h1">EFFICACY OF ALTERNATIVE FEEDING STRATEGIES</span><span class="headingEndMark"> — </span>Replacement feeding, shortened breastfeeding, and mixed feeding have been assessed to determine if alternative strategies in infant nutrition may limit the risk of HIV, in the absence of antiretroviral drug interventions. As discussed below, all of these approaches have their limitations.</p><p class="headingAnchor" id="H13613019"><span class="h2">Replacement feeding</span><span class="headingEndMark"> — </span>Avoidance of breastfeeding is a certain way to prevent HIV transmission via breast milk during the postnatal period [<a href="#rid106">106</a>]. However, in resource-limited countries, replacement feeding is associated with other significant risks, such as increased infant morbidity and mortality from diarrheal disease, pneumonia, and other infectious diseases, thus limiting the utility of this option [<a href="#rid107">107-112</a>]. Decreased rates of overall morbidity and mortality in infants who breastfeed have been attributed to protective antibodies passed from mother to infant in breast milk and decreased exposure to infectious pathogens via unsafe water [<a href="#rid45">45</a>].</p><p>In a few areas with access to clean water supplies (eg, Nairobi), replacement feeding has been associated with significantly lower rates of HIV transmission compared with breastfeeding [<a href="#rid113">113</a>]. However, this trial preceded antiretroviral prophylaxis studies that demonstrated marked efficacy of decreasing transmission of HIV in both replacement feeding and breastfeeding females [<a href="#rid114">114-116</a>]. Thus, in the context of antiretroviral medications, the benefits of replacement feeding (eg, improving HIV-free survival) are no longer retained in resource-limited settings [<a href="#rid117">117</a>]. </p><p class="headingAnchor" id="H13613026"><span class="h2">Shortened breastfeeding</span><span class="headingEndMark"> — </span>Some studies have suggested that a shortened course of breastfeeding may be somewhat protective against HIV infant transmission [<a href="#rid118">118</a>]. In order to limit the risk of HIV transmission and to facilitate the benefits of passive maternal antibody transfer, prior WHO guidelines recommended breastfeeding for a limited period of time (eg, six months). However, subsequent studies noted increased infant morbidity, mortality, and growth compromise with early breastfeeding cessation compared with longer periods of breastfeeding [<a href="#rid119">119-122</a>]. Furthermore, in a study of Zambian Exclusive Breastfeeding, HIV-free survival was found to be similar among infants who abruptly stopped breastfeeding at four months and those who continued for longer periods of time [<a href="#rid123">123</a>]. (See <a class="local">'Timing of HIV transmission through breast milk'</a> above.)</p><p>Finally, with expanded antiretroviral drug availability in resource-limited settings, the risk of breast milk-associated HIV transmission becomes low, making early breastfeeding cessation relatively more risky than longer periods of breastfeeding, in terms of nutrition and other benefits. </p><p class="headingAnchor" id="H13613033"><span class="h2">Mixed feeding</span><span class="headingEndMark"> — </span>Although it might be anticipated that mixed feeding (eg, breastfeeding combined with other types of liquids or solids) might be associated with a lower risk of HIV transmission compared with exclusive breastfeeding due to less exposure to HIV-infected breast milk, studies have not supported this hypothesis. </p><p>Several studies from South Africa, Zambia, West Africa, and Zimbabwe have demonstrated that mixed feeding during the first three to six months of life is associated with an increased risk of infant HIV transmission compared with breastfeeding alone in infants of mothers not receiving antiretroviral therapy [<a href="#rid48">48-50,124</a>]. The reason for this observation is not well understood; some have suggested that infants may have greater exposure to infectious agents through liquids or solids, which compromise gut integrity, allowing for HIV transmission [<a href="#rid125">125</a>]. In the context of maternal antiretroviral use and infant prophylaxis, the relative influence of mixed feeding on breast milk HIV transmission may be attenuated, however, exclusive breastfeeding confers many benefits independent of HIV and should be supported in all females regardless of HIV infection.</p><p class="headingAnchor" id="H1782295445"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111625.html" rel="external">"Society guideline links: HIV treatment in pregnant patients"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/111345.html" rel="external">"Society guideline links: Breastfeeding and infant nutrition"</a>.)</p><p class="headingAnchor" id="H449464"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Vertical HIV transmission occurs in utero, peripartum, and postnatally via breastfeeding; the risk of HIV transmission to the infant is significantly reduced with antiretroviral medications. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of HIV transmission through breast milk is greatest in the first several months of life; however, a lower but constant risk persists throughout the entire breastfeeding period. The risk also increases with increased levels of maternal HIV RNA in plasma or breast milk. (See <a class="local">'Timing of HIV transmission through breast milk'</a> above and <a class="local">'Risk factors for HIV transmission through breast milk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In resource-limited settings, replacement feeding is associated with greater infant morbidity and mortality from diarrheal disease, pneumonia, and other infectious diseases. Therefore, the World Health Organization (WHO) recommends breastfeeding with antiretroviral interventions (maternal antiretroviral therapy [ART] and short-term infant antiretroviral prophylaxis) in such settings to prevent transmission. (See <a class="local">'Options for infant feeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In such settings, exclusive breastfeeding in combination with ART, is recommended for the first six months of life. Subsequently, breastfeeding, along with ART, adherence support, and appropriate complementary feeding should continue up to 24 months or longer, similar to the general population. (See <a class="local">'Exclusive breastfeeding protocol'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The WHO recommends that ART be initiated in all individuals with HIV, including pregnant and breastfeeding females, regardless of CD4 cell count or clinical stage, and continued lifelong. A once-daily, fixed-dose combination of tenofovir, <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> (or <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">emtricitabine</a>), and <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> is the preferred first-line regimen. (See <a class="local">'Maternal antiretroviral use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiretroviral medications significantly decrease the risk of vertical transmission of HIV during the antepartum, intrapartum, and early postpartum periods. However, risk of HIV transmission recurs if antiretrovirals are discontinued during the breastfeeding period. Although maternal and infant antiretroviral prophylaxis strategies during the breastfeeding period are comparably effective in reducing the rate of transmission, maternal ART is the preferred strategy, as it is recommended for all individuals with HIV and is essential for maternal health. (See <a class="local">'Efficacy of antiretroviral drugs to prevent transmission during breastfeeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although there is strong evidence that HIV is not transmitted sexually when the viral load is undetectable, breast milk transmission may still occur despite plasma viral suppression. (See <a class="local">'Transmission risk despite viral suppression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infant antiretroviral use remains important as postexposure prophylaxis after delivery and in settings in which maternal antiretroviral use is delayed or interrupted during breastfeeding  (<a class="graphic graphic_table graphicRef108738" href="/z/d/graphic/108738.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef108808" href="/z/d/graphic/108808.html" rel="external">algorithm 1</a>). (See <a class="local">'Infant antiretroviral use'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">John GC, Kreiss J. Mother-to-child transmission of human immunodeficiency virus type 1. Epidemiol Rev 1996; 18:149.</a></li><li><a class="nounderline abstract_t">Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362:2271.</a></li><li><a class="nounderline abstract_t">Flynn PM, Taha TE, Cababasay M, et al. Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial. J Acquir Immune Defic Syndr 2018; 77:383.</a></li><li class="breakAll">UNAIDS. Start free stay free AIDS free - 2019 report. https://www.unaids.org/en/resources/documents/2019/20190722_UNAIDS_SFSFAF_2019 (Accessed on October 09, 2019).</li><li><a class="nounderline abstract_t">Goedhals D, Rossouw I, Hallbauer U, et al. The tainted milk of human kindness. Lancet 2012; 380:702.</a></li><li><a class="nounderline abstract_t">Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992; 327:1246.</a></li><li><a class="nounderline abstract_t">Van de Perre P, Simonon A, Msellati P, et al. Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. A prospective cohort study in Kigali, Rwanda. N Engl J Med 1991; 325:593.</a></li><li><a class="nounderline abstract_t">Rousseau CM, Nduati RW, Richardson BA, et al. Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis 2004; 190:1880.</a></li><li><a class="nounderline abstract_t">Koulinska IN, Villamor E, Chaplin B, et al. Transmission of cell-free and cell-associated HIV-1 through breast-feeding. J Acquir Immune Defic Syndr 2006; 41:93.</a></li><li><a class="nounderline abstract_t">Nduati R, Mbori-Ngacha D, John G, et al. Breastfeeding in women with HIV. JAMA 2000; 284:956.</a></li><li><a class="nounderline abstract_t">Miotti PG, Taha TE, Kumwenda NI, et al. HIV transmission through breastfeeding: a study in Malawi. JAMA 1999; 282:744.</a></li><li><a class="nounderline abstract_t">Breastfeeding and HIV International Transmission Study Group, Coutsoudis A, Dabis F, et al. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004; 189:2154.</a></li><li><a class="nounderline abstract_t">Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362:2282.</a></li><li><a class="nounderline abstract_t">John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001; 183:206.</a></li><li><a class="nounderline abstract_t">Sabbaj S, Ghosh MK, Edwards BH, et al. Breast milk-derived antigen-specific CD8+ T cells: an extralymphoid effector memory cell population in humans. J Immunol 2005; 174:2951.</a></li><li><a class="nounderline abstract_t">Rousseau CM, Nduati RW, Richardson BA, et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis 2003; 187:741.</a></li><li><a class="nounderline abstract_t">Ndirangu J, Viljoen J, Bland RM, et al. Cell-free (RNA) and cell-associated (DNA) HIV-1 and postnatal transmission through breastfeeding. PLoS One 2012; 7:e51493.</a></li><li><a class="nounderline abstract_t">Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. PLoS Med 2014; 11:e1001608.</a></li><li><a class="nounderline abstract_t">Van de Perre P, Simonon A, Hitimana DG, et al. Infective and anti-infective properties of breastmilk from HIV-1-infected women. Lancet 1993; 341:914.</a></li><li><a class="nounderline abstract_t">Pollara J, McGuire E, Fouda GG, et al. Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. J Virol 2015; 89:9952.</a></li><li><a class="nounderline abstract_t">Mabuka J, Nduati R, Odem-Davis K, et al. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 2012; 8:e1002739.</a></li><li><a class="nounderline abstract_t">Lohman-Payne B, Slyker JA, Moore S, et al. Breast milk cellular HIV-specific interferon γ responses are associated with protection from peripartum HIV transmission. AIDS 2012; 26:2007.</a></li><li><a class="nounderline abstract_t">Farquhar C, VanCott T, Bosire R, et al. Salivary human immunodeficiency virus (HIV)-1-specific immunoglobulin A in HIV-1-exposed infants in Kenya. Clin Exp Immunol 2008; 153:37.</a></li><li><a class="nounderline abstract_t">Farquhar C, Mbori-Ngacha DA, Redman MW, et al. CC and CXC chemokines in breastmilk are associated with mother-to-child HIV-1 transmission. Curr HIV Res 2005; 3:361.</a></li><li><a class="nounderline abstract_t">Tiemessen CT, Kuhn L. CC chemokines and protective immunity: insights gained from mother-to-child transmission of HIV. Nat Immunol 2007; 8:219.</a></li><li><a class="nounderline abstract_t">Lehman DA, Farquhar C. Biological mechanisms of vertical human immunodeficiency virus (HIV-1) transmission. Rev Med Virol 2007; 17:381.</a></li><li><a class="nounderline abstract_t">Boyce CL, Sils T, Ko D, et al. Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants. Clin Infect Dis 2022; 74:2001.</a></li><li><a class="nounderline abstract_t">Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 1999; 180:93.</a></li><li><a class="nounderline abstract_t">Semba RD, Kumwenda N, Taha TE, et al. Mastitis and immunological factors in breast milk of lactating women in Malawi. Clin Diagn Lab Immunol 1999; 6:671.</a></li><li><a class="nounderline abstract_t">Semba RD, Kumwenda N, Taha TE, et al. Mastitis and immunological factors in breast milk of human immunodeficiency virus-infected women. J Hum Lact 1999; 15:301.</a></li><li><a class="nounderline abstract_t">Semba RD, Neville MC. Breast-feeding, mastitis, and HIV transmission: nutritional implications. Nutr Rev 1999; 57:146.</a></li><li><a class="nounderline abstract_t">Willumsen JF, Filteau SM, Coutsoudis A, et al. Breastmilk RNA viral load in HIV-infected South African women: effects of subclinical mastitis and infant feeding. AIDS 2003; 17:407.</a></li><li><a class="nounderline abstract_t">Van de Perre P, Lepage P, Homsy J, Dabis F. Mother-to-infant transmission of human immunodeficiency virus by breast milk: presumed innocent or presumed guilty? Clin Infect Dis 1992; 15:502.</a></li><li><a class="nounderline abstract_t">Shen R, Smythies LE, Clements RH, et al. Dendritic cells transmit HIV-1 through human small intestinal mucosa. J Leukoc Biol 2010; 87:663.</a></li><li><a class="nounderline abstract_t">Veazey R, Lackner A. The mucosal immune system and HIV-1 infection. AIDS Rev 2003; 5:245.</a></li><li><a class="nounderline abstract_t">Lapenta C, Boirivant M, Marini M, et al. Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection. Eur J Immunol 1999; 29:1202.</a></li><li><a class="nounderline abstract_t">Kourtis AP, Ibegbu CC, Wiener J, et al. Role of intestinal mucosal integrity in HIV transmission to infants through breast-feeding: the BAN study. J Infect Dis 2013; 208:653.</a></li><li><a class="nounderline abstract_t">Abel K, Pahar B, Van Rompay KK, et al. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. J Virol 2006; 80:6357.</a></li><li><a class="nounderline abstract_t">Milush JM, Kosub D, Marthas M, et al. Rapid dissemination of SIV following oral inoculation. AIDS 2004; 18:2371.</a></li><li><a class="nounderline abstract_t">Tugizov SM, Herrera R, Veluppillai P, et al. Differential transmission of HIV traversing fetal oral/intestinal epithelia and adult oral epithelia. J Virol 2012; 86:2556.</a></li><li class="breakAll">World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. https://www.who.int/publications-detail-redirect/9789240031593 (Accessed on February 08, 2023).</li><li><a class="nounderline abstract_t">Currier JS, Britto P, Hoffman RM, et al. Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3. PLoS One 2017; 12:e0176009.</a></li><li class="breakAll">World Health Organization. Breastfeeding and HIV. https://apps.who.int/iris/bitstream/handle/10665/279781/WHO-NMH-NHD-18.14-eng.pdf?ua=1 (Accessed on October 09, 2019).</li><li><a class="nounderline abstract_t">Arikawa S, Rollins N, Jourdain G, et al. Contribution of Maternal Antiretroviral Therapy and Breastfeeding to 24-Month Survival in Human Immunodeficiency Virus-Exposed Uninfected Children: An Individual Pooled Analysis of African and Asian Studies. Clin Infect Dis 2018; 66:1668.</a></li><li><a class="nounderline abstract_t">Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. Lancet 2000; 355:451.</a></li><li class="breakAll">World Health Organization. Guideline: Updates on HIV and infant feeding. https://www.who.int/publications/i/item/9789241549707 (Accessed on February 23, 2017).</li><li><a class="nounderline abstract_t">Coutsoudis A, Kuhn L, Pillay K, Coovadia HM. Exclusive breast-feeding and HIV transmission. AIDS 2002; 16:498.</a></li><li><a class="nounderline abstract_t">Iliff PJ, Piwoz EG, Tavengwa NV, et al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS 2005; 19:699.</a></li><li><a class="nounderline abstract_t">Coovadia HM, Rollins NC, Bland RM, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 2007; 369:1107.</a></li><li><a class="nounderline abstract_t">Kuhn L, Sinkala M, Kankasa C, et al. High uptake of exclusive breastfeeding and reduced early post-natal HIV transmission. PLoS One 2007; 2:e1363.</a></li><li><a class="nounderline abstract_t">Tomlinson M, Doherty T, Ijumba P, et al. Goodstart: a cluster randomised effectiveness trial of an integrated, community-based package for maternal and newborn care, with prevention of mother-to-child transmission of HIV in a South African township. Trop Med Int Health 2014; 19:256.</a></li><li><a class="nounderline abstract_t">Mpody C, Reline T, Ravelomanana NLR, et al. Breastfeeding Support Offered at Delivery is Associated with Higher Prevalence of Exclusive Breastfeeding at 6 Weeks Postpartum Among HIV Exposed Infants: A Cross-Sectional Analysis. Matern Child Health J 2019; 23:1308.</a></li><li><a class="nounderline abstract_t">Fowler MG, Qin M, Fiscus SA, et al. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. N Engl J Med 2016; 375:1726.</a></li><li><a class="nounderline abstract_t">Dinh TH, Mushavi A, Shiraishi RW, et al. Impact of Timing of Antiretroviral Treatment and Birth Weight on Mother-to-Child Human Immunodeficiency Virus Transmission: Findings From an 18-Month Prospective Cohort of a Nationally Representative Sample of Mother-Infant Pairs During the Transition From Option A to Option B+ in Zimbabwe. Clin Infect Dis 2018; 66:576.</a></li><li><a class="nounderline abstract_t">Zash R, Holmes L, Diseko M, et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med 2019; 381:827.</a></li><li><a class="nounderline abstract_t">Raesima MM, Ogbuabo CM, Thomas V, et al. Dolutegravir Use at Conception - Additional Surveillance Data from Botswana. N Engl J Med 2019; 381:885.</a></li><li class="breakAll">Zash R, Holmes K, Diseko M, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. Presented at the 24th International AIDS Conference, July 2022.</li><li><a class="nounderline abstract_t">Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251.</a></li><li><a class="nounderline abstract_t">Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J Infect Dis 2008; 197:1006.</a></li><li><a class="nounderline abstract_t">Lockman S, Brummel SS, Ziemba L, et al. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 2021; 397:1276.</a></li><li><a class="nounderline abstract_t">Waitt C, Orrell C, Walimbwa S, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLoS Med 2019; 16:e1002895.</a></li><li class="breakAll">Conference on Retroviruses and Opportunisitic Infections. DolPHIN2 FINAL RESULTS DOLUTEGRAVIR VS EFAVIRENZ IN LATE PREGNANCY TO 72W POSTPARTUM. DolPHIN2 FINAL RESULTS DOLUTEGRAVIR VS EFAVIRENZ IN LATE PREGNANCY TO 72W POSTPARTUM (Accessed on October 25, 2021).</li><li><a class="nounderline abstract_t">Cohan D, Natureeba P, Koss CA, et al. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. AIDS 2015; 29:183.</a></li><li><a class="nounderline abstract_t">Fayorsey RN, Wang C, Chege D, et al. Effectiveness of a Lay Counselor-Led Combination Intervention for Retention of Mothers and Infants in HIV Care: A Randomized Trial in Kenya. J Acquir Immune Defic Syndr 2019; 80:56.</a></li><li><a class="nounderline abstract_t">Ambia J, Mandala J. A systematic review of interventions to improve prevention of mother-to-child HIV transmission service delivery and promote retention. J Int AIDS Soc 2016; 19:20309.</a></li><li><a class="nounderline abstract_t">Yotebieng M, Thirumurthy H, Moracco KE, et al. Conditional cash transfers and uptake of and retention in prevention of mother-to-child HIV transmission care: a randomised controlled trial. Lancet HIV 2016; 3:e85.</a></li><li><a class="nounderline abstract_t">Odeny TA, Hughes JP, Bukusi EA, et al. Text messaging for maternal and infant retention in prevention of mother-to-child HIV transmission services: A pragmatic stepped-wedge cluster-randomized trial in Kenya. PLoS Med 2019; 16:e1002924.</a></li><li><a class="nounderline abstract_t">John-Stewart G. eHealth and Prevention of Mother-to-Child Transmission of HIV. Curr HIV/AIDS Rep 2018; 15:350.</a></li><li><a class="nounderline abstract_t">Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8:e1000430.</a></li><li><a class="nounderline abstract_t">Fogel J, Li Q, Taha TE, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis 2011; 52:1069.</a></li><li><a class="nounderline abstract_t">Nelson JA, Fokar A, Hudgens MG, et al. Frequent nevirapine resistance in infants infected by HIV-1 via breastfeeding while on nevirapine prophylaxis. AIDS 2015; 29:2131.</a></li><li><a class="nounderline abstract_t">Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217.</a></li><li><a class="nounderline abstract_t">Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173.</a></li><li><a class="nounderline abstract_t">Leroy V, Newell ML, Dabis F, et al. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Ghent International Working Group on Mother-to-Child Transmission of HIV. Lancet 1998; 352:597.</a></li><li><a class="nounderline abstract_t">Kesho Bora Study Group, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171.</a></li><li><a class="nounderline abstract_t">Marazzi MC, Nielsen-Saines K, Buonomo E, et al. Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding. Pediatr Infect Dis J 2009; 28:483.</a></li><li><a class="nounderline abstract_t">White AB, Mirjahangir JF, Horvath H, et al. Antiretroviral interventions for preventing breast milk transmission of HIV. Cochrane Database Syst Rev 2014; :CD011323.</a></li><li><a class="nounderline abstract_t">Taha TE, Kumwenda J, Cole SR, et al. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. J Infect Dis 2009; 200:1490.</a></li><li><a class="nounderline abstract_t">Thomas TK, Masaba R, Borkowf CB, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding--the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 2011; 8:e1001015.</a></li><li><a class="nounderline abstract_t">Luoga E, Vanobberghen F, Bircher R, et al. Brief Report: No HIV Transmission From Virally Suppressed Mothers During Breastfeeding in Rural Tanzania. J Acquir Immune Defic Syndr 2018; 79:e17.</a></li><li><a class="nounderline abstract_t">Mofenson LM. Protecting the next generation--eliminating perinatal HIV-1 infection. N Engl J Med 2010; 362:2316.</a></li><li><a class="nounderline abstract_t">Shapiro RL, Kitch D, Ogwu A, et al. HIV transmission and 24-month survival in a randomized trial of HAART to prevent MTCT during pregnancy and breastfeeding in Botswana. AIDS 2013; 27:1911.</a></li><li><a class="nounderline abstract_t">Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2011; :CD003510.</a></li><li><a class="nounderline abstract_t">Six Week Extended-Dose Nevirapine (SWEN) Study Team, Bedri A, Gudetta B, et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008; 372:300.</a></li><li><a class="nounderline abstract_t">Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008; 359:119.</a></li><li><a class="nounderline abstract_t">Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 379:221.</a></li><li><a class="nounderline abstract_t">Hudgens MG, Taha TE, Omer SB, et al. Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission. Clin Infect Dis 2013; 56:131.</a></li><li><a class="nounderline abstract_t">Fowler MG, Coovadia H, Herron CM, et al. Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr 2014; 65:366.</a></li><li><a class="nounderline abstract_t">Nagot N, Kankasa C, Tumwine JK, et al. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet 2016; 387:566.</a></li><li><a class="nounderline abstract_t">Jamieson DJ, Chasela CS, Hudgens MG, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet 2012; 379:2449.</a></li><li><a class="nounderline abstract_t">Waitt C, Low N, Van de Perre P, et al. Does U=U for breastfeeding mothers and infants? Breastfeeding by mothers on effective treatment for HIV infection in high-income settings. Lancet HIV 2018; 5:e531.</a></li><li><a class="nounderline abstract_t">Bispo S, Chikhungu L, Rollins N, et al. Postnatal HIV transmission in breastfed infants of HIV-infected women on ART: a systematic review and meta-analysis. J Int AIDS Soc 2017; 20:21251.</a></li><li><a class="nounderline abstract_t">Flynn PM, Taha TE, Cababasay M, et al. Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum Component. J Acquir Immune Defic Syndr 2021; 88:206.</a></li><li><a class="nounderline abstract_t">Waitt CJ, Garner P, Bonnett LJ, et al. Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. J Antimicrob Chemother 2015; 70:1928.</a></li><li><a class="nounderline abstract_t">Waitt C, Olagunju A, Nakalema S, et al. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. J Antimicrob Chemother 2018; 73:1013.</a></li><li><a class="nounderline abstract_t">Mugwanya KK, Hendrix CW, Mugo NR, et al. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption. PLoS Med 2016; 13:e1002132.</a></li><li><a class="nounderline abstract_t">Dickinson L, Walimbwa S, Singh Y, et al. Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1. Clin Infect Dis 2021; 73:e1200.</a></li><li><a class="nounderline abstract_t">Kobbe R, Schalkwijk S, Dunay G, et al. Dolutegravir in breast milk and maternal and infant plasma during breastfeeding. AIDS 2016; 30:2731.</a></li><li><a class="nounderline abstract_t">Dryden-Peterson S, Shapiro RL, Hughes MD, et al. Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. J Acquir Immune Defic Syndr 2011; 56:428.</a></li><li><a class="nounderline abstract_t">Feiterna-Sperling C, Weizsaecker K, Bührer C, et al. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants. J Acquir Immune Defic Syndr 2007; 45:43.</a></li><li><a class="nounderline abstract_t">Heidari S, Mofenson L, Cotton MF, et al. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr 2011; 57:290.</a></li><li><a class="nounderline abstract_t">Palombi L, Pirillo MF, Marchei E, et al. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. J Antimicrob Chemother 2016; 71:1027.</a></li><li><a class="nounderline abstract_t">Floridia M, Liotta G, Andreotti M, et al. Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi. J Antimicrob Chemother 2016; 71:3206.</a></li><li><a class="nounderline abstract_t">Liotta G, Floridia M, Andreotti M, et al. Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants. AIDS 2016; 30:525.</a></li><li><a class="nounderline abstract_t">Kilewo C, Karlsson K, Massawe A, et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr 2008; 48:315.</a></li><li><a class="nounderline abstract_t">John-Stewart GC. When is replacement feeding safe for infants of HIV-infected women? PLoS Med 2007; 4:e30.</a></li><li><a class="nounderline abstract_t">Kuhn L, Stein Z. Infant survival, HIV infection, and feeding alternatives in less-developed countries. Am J Public Health 1997; 87:926.</a></li><li><a class="nounderline abstract_t">Phadke MA, Gadgil B, Bharucha KE, et al. Replacement-fed infants born to HIV-infected mothers in India have a high early postpartum rate of hospitalization. J Nutr 2003; 133:3153.</a></li><li><a class="nounderline abstract_t">Homsy J, Moore D, Barasa A, et al. Breastfeeding, mother-to-child HIV transmission, and mortality among infants born to HIV-Infected women on highly active antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr 2010; 53:28.</a></li><li><a class="nounderline abstract_t">Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 2006; 296:794.</a></li><li><a class="nounderline abstract_t">Natchu UC, Liu E, Duggan C, et al. Exclusive breastfeeding reduces risk of mortality in infants up to 6 mo of age born to HIV-positive Tanzanian women. Am J Clin Nutr 2012; 96:1071.</a></li><li><a class="nounderline abstract_t">Yeganeh N, Watts DH, Xu J, et al. Infectious Morbidity, Mortality and Nutrition in HIV-exposed, Uninfected, Formula-fed Infants: Results From the HPTN 040/PACTG 1043 Trial. Pediatr Infect Dis J 2018; 37:1271.</a></li><li><a class="nounderline abstract_t">Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000; 283:1167.</a></li><li><a class="nounderline abstract_t">Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999; 353:773.</a></li><li><a class="nounderline abstract_t">Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795.</a></li><li><a class="nounderline abstract_t">Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999; 353:781.</a></li><li><a class="nounderline abstract_t">Kuhn L, Reitz C, Abrams EJ. Breastfeeding and AIDS in the developing world. Curr Opin Pediatr 2009; 21:83.</a></li><li><a class="nounderline abstract_t">Tonwe-Gold B, Ekouevi DK, Viho I, et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med 2007; 4:e257.</a></li><li><a class="nounderline abstract_t">Kafulafula G, Hoover DR, Taha TE, et al. Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi. J Acquir Immune Defic Syndr 2010; 53:6.</a></li><li><a class="nounderline abstract_t">Onyango-Makumbi C, Bagenda D, Mwatha A, et al. Early weaning of HIV-exposed uninfected infants and risk of serious gastroenteritis: Findings from two perinatal HIV prevention trials in Kampala, Uganda. J Acquir Immune Defic Syndr 2010; 53:20.</a></li><li><a class="nounderline abstract_t">Arpadi S, Fawzy A, Aldrovandi GM, et al. Growth faltering due to breastfeeding cessation in uninfected children born to HIV-infected mothers in Zambia. Am J Clin Nutr 2009; 90:344.</a></li><li><a class="nounderline abstract_t">Simondon KB. Early breast-feeding cessation and infant mortality in low-income countries: workshop summary. Adv Exp Med Biol 2009; 639:319.</a></li><li><a class="nounderline abstract_t">Kuhn L, Aldrovandi GM, Sinkala M, et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Engl J Med 2008; 359:130.</a></li><li><a class="nounderline abstract_t">Becquet R, Bland R, Leroy V, et al. Duration, pattern of breastfeeding and postnatal transmission of HIV: pooled analysis of individual data from West and South African cohorts. PLoS One 2009; 4:e7397.</a></li><li><a class="nounderline abstract_t">Rollins NC, Filteau SM, Coutsoudis A, Tomkins AM. Feeding mode, intestinal permeability, and neopterin excretion: a longitudinal study in infants of HIV-infected South African women. J Acquir Immune Defic Syndr 2001; 28:132.</a></li></ol></div><div id="topicVersionRevision">Topic 13970 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9021309" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mother-to-child transmission of human immunodeficiency virus type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20554982" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29239901" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29239901" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22901892" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The tainted milk of human kindness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1406816" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Proposed definitions for in utero versus intrapartum transmission of HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1812850" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. A prospective cohort study in Kigali, Rwanda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15499546" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16340480" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Transmission of cell-free and cell-associated HIV-1 through breast-feeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10944630" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Breastfeeding in women with HIV</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10463709" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : HIV transmission through breastfeeding: a study in Malawi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15181561" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20554983" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antiretroviral regimens in pregnancy and breast-feeding in Botswana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11120927" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728507" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Breast milk-derived antigen-specific CD8+ T cells: an extralymphoid effector memory cell population in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12599047" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23284701" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cell-free (RNA) and cell-associated (DNA) HIV-1 and postnatal transmission through breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24586123" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8096264" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Infective and anti-infective properties of breastmilk from HIV-1-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26202232" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22719248" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22948269" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Breast milk cellular HIV-specific interferonγresponses are associated with protection from peripartum HIV transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18505437" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Salivary human immunodeficiency virus (HIV)-1-specific immunoglobulin A in HIV-1-exposed infants in Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16250882" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : CC and CXC chemokines in breastmilk are associated with mother-to-child HIV-1 transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17304227" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : CC chemokines and protective immunity: insights gained from mother-to-child transmission of HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17542053" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Biological mechanisms of vertical human immunodeficiency virus (HIV-1) transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34467974" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10353866" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10473515" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mastitis and immunological factors in breast milk of lactating women in Malawi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10776180" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mastitis and immunological factors in breast milk of human immunodeficiency virus-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10391017" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Breast-feeding, mastitis, and HIV transmission: nutritional implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12556695" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Breastmilk RNA viral load in HIV-infected South African women: effects of subclinical mastitis and infant feeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1445596" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mother-to-infant transmission of human immunodeficiency virus by breast milk: presumed innocent or presumed guilty?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20007245" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Dendritic cells transmit HIV-1 through human small intestinal mucosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15012003" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The mucosal immune system and HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10229087" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687226" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Role of intestinal mucosal integrity in HIV transmission to infants through breast-feeding: the BAN study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16775324" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15622313" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Rapid dissemination of SIV following oral inoculation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22205732" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Differential transmission of HIV traversing fetal oral/intestinal epithelia and adult oral epithelia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22205732" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Differential transmission of HIV traversing fetal oral/intestinal epithelia and adult oral epithelia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28489856" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4≥400 cells/mm3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28489856" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4≥400 cells/mm3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29272387" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Contribution of Maternal Antiretroviral Therapy and Breastfeeding to 24-Month Survival in Human Immunodeficiency Virus-Exposed Uninfected Children: An Individual Pooled Analysis of African and Asian Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10841125" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10841125" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11834968" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Exclusive breast-feeding and HIV transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15821396" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17398310" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18159246" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : High uptake of exclusive breastfeeding and reduced early post-natal HIV transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24433230" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Goodstart: a cluster randomised effectiveness trial of an integrated, community-based package for maternal and newborn care, with prevention of mother-to-child transmission of HIV in a South African township.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31214949" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Breastfeeding Support Offered at Delivery is Associated with Higher Prevalence of Exclusive Breastfeeding at 6 Weeks Postpartum Among HIV Exposed Infants: A Cross-Sectional Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27806243" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29401270" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impact of Timing of Antiretroviral Treatment and Birth Weight on Mother-to-Child Human Immunodeficiency Virus Transmission: Findings From an 18-Month Prospective Cohort of a Nationally Representative Sample of Mother-Infant Pairs During the Transition From Option A to Option B+ in Zimbabwe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31329379" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31329378" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Dolutegravir Use at Conception - Additional Surveillance Data from Botswana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31329378" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Dolutegravir Use at Conception - Additional Surveillance Data from Botswana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421366" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419537" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33812487" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31539371" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31539371" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25426808" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30399035" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effectiveness of a Lay Counselor-Led Combination Intervention for Retention of Mothers and Infants in HIV Care: A Randomized Trial in Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27056361" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A systematic review of interventions to improve prevention of mother-to-child HIV transmission service delivery and promote retention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26847230" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Conditional cash transfers and uptake of and retention in prevention of mother-to-child HIV transmission care: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31577792" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Text messaging for maternal and infant retention in prevention of mother-to-child HIV transmission services: A pragmatic stepped-wedge cluster-randomized trial in Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29931467" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : eHealth and Prevention of Mother-to-Child Transmission of HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21468304" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460326" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26186128" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Frequent nevirapine resistance in infants infected by HIV-1 via breastfeeding while on nevirapine prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15247338" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7935654" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9746019" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Ghent International Working Group on Mother-to-Child Transmission of HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21237718" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19483516" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25280769" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Antiretroviral interventions for preventing breast milk transmission of HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19832114" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21468300" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding--the Kisumu Breastfeeding Study, Kenya: a clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29781882" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Brief Report: No HIV Transmission From Virally Suppressed Mothers During Breastfeeding in Rural Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20554987" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Protecting the next generation--eliminating perinatal HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24180000" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : HIV transmission and 24-month survival in a randomized trial of HAART to prevent MTCT during pregnancy and breastfeeding in Botswana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21735394" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18657709" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18525035" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22196945" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22997212" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24189151" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26603917" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22541418" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29960731" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Does U=U for breastfeeding mothers and infants? Breastfeeding by mothers on effective treatment for HIV infection in high-income settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28362072" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Postnatal HIV transmission in breastfed infants of HIV-infected women on ART: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34108383" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum Component.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25858354" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29309634" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27676257" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33346335" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27782968" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Dolutegravir in breast milk and maternal and infant plasma during breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21266910" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Increased risk of severe infant anemia after exposure to maternal HAART, Botswana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17356471" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21602695" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679247" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27494909" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26765942" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18344879" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17227137" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : When is replacement feeding safe for infants of HIV-infected women?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9224171" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Infant survival, HIV infection, and feeding alternatives in less-developed countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14519801" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Replacement-fed infants born to HIV-infected mothers in India have a high early postpartum rate of hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797972" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Breastfeeding, mother-to-child HIV transmission, and mortality among infants born to HIV-Infected women on highly active antiretroviral therapy in rural Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16905785" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23053555" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Exclusive breastfeeding reduces risk of mortality in infants up to 6 mo of age born to HIV-positive Tanzanian women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29750766" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Infectious Morbidity, Mortality and Nutrition in HIV-exposed, Uninfected, Formula-fed Infants: Results From the HPTN 040/PACTG 1043 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10703779" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10459957" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10485720" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10459958" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19242244" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Breastfeeding and AIDS in the developing world.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17713983" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19844183" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19779355" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Early weaning of HIV-exposed uninfected infants and risk of serious gastroenteritis: Findings from two perinatal HIV prevention trials in Kampala, Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19553300" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Growth faltering due to breastfeeding cessation in uninfected children born to HIV-infected mothers in Zambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19227552" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Early breast-feeding cessation and infant mortality in low-income countries: workshop summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18525036" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Effects of early, abrupt weaning on HIV-free survival of children in Zambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19834601" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Duration, pattern of breastfeeding and postnatal transmission of HIV: pooled analysis of individual data from West and South African cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11588506" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Feeding mode, intestinal permeability, and neopterin excretion: a longitudinal study in infants of HIV-infected South African women.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
